Press release
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.Download the sample report @ https://www.pharmaproff.com/request-sample/1164
Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased appetite and nausea.
In advanced renal cell carcinoma, which is a form of kidney cancer, Cabozantinib is used in those patients who have been previously treated with a type of cancer medicine called ‘vascular endothelial growth factor (VEGF) inhibitor.
Get the detailed analysis @ https://www.pharmaproff.com/report/cabozantinib
It is also used in patients who have not undergone previous treatment and whose cancer is at moderate or high risk. In hepatocellular carcinoma, which is a form of liver cancer, it is used in patients who have already been treated with the cancer medicine such as Sorafenib. It is currently marketed in Europe and the U.S.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1164
This report provides details of the drug and the API manufacturers across the 7 major markets which includes U.S, EU5, and Japan. It includes the overview, mechanism, regulatory milestones, strategic developments, the historical and forecasted sales. The pipeline analysis of the drug by phase which would include the product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cabozantinib- API Insight, 2018 here
News-ID: 1711171 • Views: …
More Releases for VEGF
Anti-VEGF Therapeutic Market New Product Development & Latest Trends
The global Anti-VEGF therapeutic market is projected to reach approximately $32.1 billion in 2024, driven by increasing incidences of ocular diseases such as age-related macular degeneration and diabetic retinopathy. Over the forecast period from 2025 to 2034, the market is expected to grow at a compound annual growth rate (CAGR) of around 6.2%, reaching an estimated value of $57.4 billion by 2034.
Exactitude Consultancy., Ltd. released a research report offers a…
The Increasing Prevalence Of Cancer And Macular Degeneration Diseases Drives The …
The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Size During the Forecast Period?
The market size for the inhibitor of vascular endothelial growth factor (VEGF) has seen substantial…
VEGF Inhibitor Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2 …
Market Overview and Report Coverage
VEGF inhibitor drugs are targeted therapies that block vascular endothelial growth factor (VEGF), a signaling protein that promotes blood vessel formation (angiogenesis) within tumors. By inhibiting VEGF, these drugs can effectively disrupt the supply of nutrients and oxygen to tumors, thereby inhibiting their growth and proliferation. These drugs are primarily used in the treatment of various cancers, including colorectal, renal cell, and lung cancer.
The VEGF inhibitor…
Anti-VEGF Therapeutics Market In-Deep Research and Forecast Report
The revenue of the anti-VEGF therapeutics market will increase from $12,178.0 million in 2021 at a compound annual growth rate of 1.4% from 2021 to 2030, to touch $13,812.6 million by 2030. The development of the industry is mainly driven by the approvals of the FDA to a number of drug candidates, accompanied by R&D activities.
Get the sample pages of this report at: https://www.psmarketresearch.com/market-analysis/anti-vascular-endothelial-growth-factor-therapeutics-market/report-sample
Eylea held the largest share in the…
Global VEGF/VEGFR Inhibitor Drugs Industry Research Analysis by 2020- 2025
This report also researches and evaluates the impact of Covid-19 outbreak on the VEGF/VEGFR Inhibitor Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on VEGF/VEGFR Inhibitor Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
GLOBAL INFO RESEARCH has lately published a new report titled, *Global and Japan VEGF/VEGFR Inhibitor Drugs Market 2020 by Company, Type and Application, Forecast to…
Vascular Endothelial Growth Factor (VEGF) Inhibitors Market: Competitive Dynamic …
LP INFORMATION offers a latest published report on Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Vascular Endothelial Growth Factor (VEGF) Inhibitors market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024,…
